159 related articles for article (PubMed ID: 37923232)
1. Lyotropic liquid crystalline 2D and 3D mesophases: Advanced materials for multifunctional anticancer nanosystems.
Araújo-Silva H; Teixeira PV; Gomes AC; Lúcio M; Lopes CM
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189011. PubMed ID: 37923232
[TBL] [Abstract][Full Text] [Related]
2. Lyotropic liquid crystalline phases: Drug delivery and biomedical applications.
Chavda VP; Dyawanapelly S; Dawre S; Ferreira-Faria I; Bezbaruah R; Rani Gogoi N; Kolimi P; Dave DJ; Paiva-Santos AC; Vora LK
Int J Pharm; 2023 Nov; 647():123546. PubMed ID: 37884213
[TBL] [Abstract][Full Text] [Related]
3. Lyotropic Liquid Crystalline Nanostructures as Drug Delivery Systems and Vaccine Platforms.
Chountoulesi M; Pispas S; Tseti IK; Demetzos C
Pharmaceuticals (Basel); 2022 Mar; 15(4):. PubMed ID: 35455426
[TBL] [Abstract][Full Text] [Related]
4. Intrinsic and Dynamic Heterogeneity of Nonlamellar Lyotropic Liquid Crystalline Nanodispersions.
Yaghmur A; Moghimi SM
ACS Nano; 2023 Nov; 17(22):22183-22195. PubMed ID: 37943319
[TBL] [Abstract][Full Text] [Related]
5. Lipid polymorphism in lyotropic liquid crystals for triggered release of bioactives.
Garti N; Libster D; Aserin A
Food Funct; 2012 Jul; 3(7):700-13. PubMed ID: 22592749
[TBL] [Abstract][Full Text] [Related]
6. Cubic lyotropic liquid crystals as drug delivery carriers: Physicochemical and morphological studies.
Chountoulesi M; Pippa N; Pispas S; Chrysina ED; Forys A; Trzebicka B; Demetzos C
Int J Pharm; 2018 Oct; 550(1-2):57-70. PubMed ID: 30121331
[TBL] [Abstract][Full Text] [Related]
7. Current potential and challenges in the advances of liquid crystalline nanoparticles as drug delivery systems.
Madheswaran T; Kandasamy M; Bose RJ; Karuppagounder V
Drug Discov Today; 2019 Jul; 24(7):1405-1412. PubMed ID: 31102731
[TBL] [Abstract][Full Text] [Related]
8. Bioimaging Applications of Non-Lamellar Liquid Crystalline Nanoparticles.
Murgia S; Biffi S; Fornasier M; Lippolis V; Picci G; Caltagirone C
J Nanosci Nanotechnol; 2021 May; 21(5):2742-2759. PubMed ID: 33653441
[TBL] [Abstract][Full Text] [Related]
9. Self-assembling in situ gel based on lyotropic liquid crystals containing VEGF for tissue regeneration.
Wang B; Huang Y; Huang Z; Wang H; Chen J; Pan X; Wu C
Acta Biomater; 2019 Nov; 99():84-99. PubMed ID: 31521813
[TBL] [Abstract][Full Text] [Related]
10. Advances in lyotropic liquid crystal systems for skin drug delivery.
Silvestrini AVP; Caron AL; Viegas J; Praça FG; Bentley MVLB
Expert Opin Drug Deliv; 2020 Dec; 17(12):1781-1805. PubMed ID: 32886531
[TBL] [Abstract][Full Text] [Related]
11. Affimer Tagged Cubosomes: Targeting of Carcinoembryonic Antigen Expressing Colorectal Cancer Cells Using
Pramanik A; Xu Z; Shamsuddin SH; Khaled YS; Ingram N; Maisey T; Tomlinson D; Coletta PL; Jayne D; Hughes TA; Tyler AII; Millner PA
ACS Appl Mater Interfaces; 2022 Mar; 14(9):11078-11091. PubMed ID: 35196008
[TBL] [Abstract][Full Text] [Related]
12. Non-Lamellar Lyotropic Liquid Crystalline Lipid Nanoparticles for the Next Generation of Nanomedicine.
Zhai J; Fong C; Tran N; Drummond CJ
ACS Nano; 2019 Jun; 13(6):6178-6206. PubMed ID: 31082192
[TBL] [Abstract][Full Text] [Related]
13. Cell interactions with lipid nanoparticles possessing different internal nanostructures: Liposomes, bicontinuous cubosomes, hexosomes, and discontinuous micellar cubosomes.
Yap SL; Yu H; Li S; Drummond CJ; Conn CE; Tran N
J Colloid Interface Sci; 2024 Feb; 656():409-423. PubMed ID: 38000253
[TBL] [Abstract][Full Text] [Related]
14. Cubosomes: An Emerging and Promising Drug Delivery System for Enhancing Cancer Therapy.
Singh S; Sachan K; Verma S; Singh N; Singh PK
Curr Pharm Biotechnol; 2024; 25(6):757-771. PubMed ID: 37929730
[TBL] [Abstract][Full Text] [Related]
15. Lyotropic Liquid-Crystalline Nanosystems as Drug Delivery Agents for 5-Fluorouracil: Structure and Cytotoxicity.
Astolfi P; Giorgini E; Gambini V; Rossi B; Vaccari L; Vita F; Francescangeli O; Marchini C; Pisani M
Langmuir; 2017 Oct; 33(43):12369-12378. PubMed ID: 29023126
[TBL] [Abstract][Full Text] [Related]
16. Progress and challenges of lyotropic liquid crystalline nanoparticles for innovative therapies.
Vitoria Pupo Silvestrini A; Wender Debiasi B; Garcia Praça F; Vitoria Lopes Badra Bentley M
Int J Pharm; 2022 Nov; 628():122299. PubMed ID: 36265664
[TBL] [Abstract][Full Text] [Related]
17. Interactions of biomacromolecules with reverse hexagonal liquid crystals: drug delivery and crystallization applications.
Libster D; Aserin A; Garti N
J Colloid Interface Sci; 2011 Apr; 356(2):375-86. PubMed ID: 21315366
[TBL] [Abstract][Full Text] [Related]
18. Oral Drug Delivery via Intestinal Lymphatic Transport Utilizing Lipid-Based Lyotropic Liquid Crystals.
Dinh L; Yan B
Liquids (Basel); 2023 Dec; 3(4):456-468. PubMed ID: 38711572
[TBL] [Abstract][Full Text] [Related]
19. Spotlight on Biomimetic Systems Based on Lyotropic Liquid Crystal.
de Souza JF; Pontes KD; Alves TF; Amaral VA; Rebelo MA; Hausen MA; Chaud MV
Molecules; 2017 Mar; 22(3):. PubMed ID: 28272377
[TBL] [Abstract][Full Text] [Related]
20. Lyotropic liquid crystal systems in drug delivery.
Guo C; Wang J; Cao F; Lee RJ; Zhai G
Drug Discov Today; 2010 Dec; 15(23-24):1032-40. PubMed ID: 20934534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
